Daprodustat market price reference in China

Daprodustat (Daprodustat) has not yet completed the launch of the original drug in mainland China, and has not been included in the national medical insurance catalog. Therefore, its official domestic selling price, medical insurance reimbursement ratio, and hospital purchase price are all in a state of "unannounced and unformed." For innovative drugs that have not yet been launched in China, official channels will not provide pricing information, so patients usually need to refer to overseas market prices or international generic drug prices as a preliminary reference range.

According to the overseas supply situation, original research specifications of daprostat have been launched. Common specifications include 1mg30 tablets, 2mg30 tablets, etc. Its actual selling price is affected by drug pricing systems, medical system structures and exchange rate changes in different countries. The retail price per box will likely range from about $100 to $500. As it is an oral small molecule innovative drug, this price is also in line with the international new drug pricing range. It should be emphasized that overseas prices cannot be directly converted into future domestic prices, but they can be used to understand their approximate cost range.

It is worth noting that the first batch of dapoprimostat generic drugs have been launched overseas. For example, Lucius Pharmaceuticals in Laos has launched a generic version of corresponding specifications, such as 1mg*100 tablets, the price may be around RMB 400, and will fluctuate due to the impact of international exchange rates. Generic drugs usually enter the market at a lower price based on the same active ingredients and consistent mechanism of action, thus providing a more cost-effective option for some patients who require long-term medication. However, generic drugs do not mean they can be officially used in China. Patients still need to follow local regulations and are not allowed to purchase drugs across borders without authorization.

Judging from domestic marketing trends, if daprostat enters the Chinese market in the future, pricing will often refer to the following factors: domestic pricing of similar HIF-PHI drugs such as roxadustat, national centralized procurement policies, medical insurance catalog negotiation rules, and renal anemia treatment needs assessment.

Reference materials:https://en.wikipedia.org/wiki/Daprodustat